Muchmore A V, Shifrin S, Decker J M
J Immunol. 1987 Apr 15;138(8):2547-53.
Our laboratory recently reported the purification of a unique immunosuppressive glycoprotein isolated from human pregnancy urine (7). This glycoprotein, which we term uromodulin, has a m.w. of 85,000 as assessed on SDS-PAGE and is 30% carbohydrate. Uromodulin blocks in vitro antigen-specific T cell proliferation to recall antigens such as tetanus toxoid at concentrations as low as 100 pM. This glycoprotein also blocks the in vitro generation of spontaneous monocyte-mediated cytotoxicity (7, 36). Recent evidence strongly suggests that the primary action of uromodulin is to act as a specific ligand and modulator of IL 1 (10, 33). We now report additional biochemical characterization of uromodulin, and based on three independent lines of evidence, find that its immunologic activity appears to result from its glycosylation. First, measures to alter the tertiary folding of the protein backbone of uromodulin, including succinylation or reduction and carboxymethylation, fail to significantly affect its in vitro bioactivity. Second, after extensive digestion of intact uromodulin with pronase, the majority of the in vitro bioactivity can be recovered in a single carbohydrate-rich fraction. Finally, digestion with N-glycanase (N-glycosidase F-, an enzyme specific for N-asparagine-linked oligosaccharides) and subsequent purification on thin layer chromatography yields a single complex oligosaccharide that appears to be responsible for the majority of the in vitro immunosuppression mediated by uromodulin. These data suggest that uromodulin displays N-linked carbohydrate sequences capable of down-regulating antigen-specific T cell responses in vitro. It has been suggested that endogenous lectins may play an important role as recognition molecules in mammalian, as well as more primitive immune systems (23, 24). Our in vitro biologic data strongly suggest that the carbohydrate portion of uromodulin is an excellent candidate to function as a potential lectin receptor.
我们实验室最近报道了从人妊娠尿液中分离出一种独特的免疫抑制糖蛋白并进行了纯化(7)。这种糖蛋白,我们称之为尿调节蛋白,经SDS-PAGE测定其分子量为85,000,碳水化合物含量为30%。尿调节蛋白在体外能以低至100 pM的浓度阻断抗原特异性T细胞对诸如破伤风类毒素等回忆抗原的增殖。这种糖蛋白还能阻断体外自发单核细胞介导的细胞毒性的产生(7, 36)。最近的证据有力地表明,尿调节蛋白的主要作用是作为白细胞介素1的特异性配体和调节剂(10, 33)。我们现在报告尿调节蛋白的其他生化特性,并基于三条独立的证据线发现,其免疫活性似乎源于其糖基化。首先,改变尿调节蛋白蛋白质主链三级折叠的措施,包括琥珀酰化或还原及羧甲基化,均未能显著影响其体外生物活性。其次,用链霉蛋白酶对完整的尿调节蛋白进行广泛消化后,大部分体外生物活性可在一个富含碳水化合物的单一馏分中恢复。最后,用N-聚糖酶(N-糖苷酶F,一种对N-天冬酰胺连接的寡糖具有特异性的酶)消化并随后在薄层色谱上纯化,得到一种单一的复合寡糖,它似乎是尿调节蛋白介导的大部分体外免疫抑制的原因。这些数据表明,尿调节蛋白展示出能够在体外下调抗原特异性T细胞反应的N-连接碳水化合物序列。有人提出,内源性凝集素可能作为识别分子在哺乳动物以及更原始的免疫系统中发挥重要作用(23, 24)。我们的体外生物学数据有力地表明,尿调节蛋白的碳水化合物部分是作为潜在凝集素受体发挥功能的极佳候选者。